{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:03:12Z","timestamp":1780617792448,"version":"3.54.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1053\/j.seminhematol.2025.04.004","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T21:48:24Z","timestamp":1744148904000},"page":"113-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors"],"prefix":"10.1053","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9490-7532","authenticated-orcid":false,"given":"Jorge J.","family":"Castillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7868-7469","authenticated-orcid":false,"given":"Francesco","family":"Autore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7251-4252","authenticated-orcid":false,"given":"Neil L.","family":"Berinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3868-9267","authenticated-orcid":false,"given":"Andrew R.","family":"Branagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4930-9255","authenticated-orcid":false,"given":"Carlos","family":"Fernandez de Larrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9711-1502","authenticated-orcid":false,"given":"Simone","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-364X","authenticated-orcid":false,"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4993-7828","authenticated-orcid":false,"given":"Jahanzaib","family":"Khwaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3139-8379","authenticated-orcid":false,"given":"Monique C.","family":"Minnema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8752-0644","authenticated-orcid":false,"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2188-6835","authenticated-orcid":false,"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3229-9556","authenticated-orcid":false,"given":"Josephine M.I.","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Buske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey V.","family":"Matous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6393-6154","authenticated-orcid":false,"given":"Steven P.","family":"Treon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5099-9156","authenticated-orcid":false,"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1053\/j.seminhematol.2025.04.004_bib0001","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom's Macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1053\/j.seminhematol.2025.04.004_bib0002","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1053\/j.seminhematol.2025.04.004_bib0003","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2018.78.6426","article-title":"Ibrutinib monotherapy in symptomatic, treatment-naive patients with Waldenstrom Macroglobulinemia","volume":"36","author":"Treon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.004_bib0004","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/S2352-3026(19)30210-8","article-title":"Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a single-arm, multicentre, phase 2 study","volume":"7","author":"Owen","year":"2020","journal-title":"Lancet Haematol"},{"issue":"18","key":"10.1053\/j.seminhematol.2025.04.004_bib0005","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.04.004_bib0006","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1111\/cas.14561","article-title":"A multicenter, open-label, phase II study of tirabrutinib (ONO\/GS-4059) in patients with Waldenstrom's Macroglobulinemia","volume":"111","author":"Sekiguchi","year":"2020","journal-title":"Cancer Sci"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.04.004_bib0007","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.20.00555","article-title":"Long-term follow-up of Ibrutinib monotherapy in symptomatic, previously treated patients with Waldenstrom Macroglobulinemia","volume":"39","author":"Treon","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.04.004_bib0008","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.21.00838","article-title":"Ibrutinib plus Rituximab versus Placebo plus Rituximab for Waldenstrom's macroglobulinemia: final analysis from the randomized phase III iNNOVATE study","volume":"40","author":"Buske","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.004_bib0009","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41375-021-01417-9","article-title":"Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom Macroglobulinemia","volume":"36","author":"Castillo","year":"2022","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.04.004_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101682","article-title":"Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study","volume":"52","author":"Cao","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.04.004_bib0011","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1111\/cas.15344","article-title":"Two-year outcomes of tirabrutinib monotherapy in Waldenstrom's Macroglobulinemia","volume":"113","author":"Sekiguchi","year":"2022","journal-title":"Cancer Sci"},{"issue":"S3","key":"10.1053\/j.seminhematol.2025.04.004_bib0012","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1097\/01.HS9.0000847388.33116.c7","article-title":"P1130: Acalabrutinib in treatment-naive or relapsed\/refractory Waldenstr\u00f6m Macroglobulinemia: 5-year follow-up of a phase 2, single-arm study","volume":"6","author":"Owen","year":"2022","journal-title":"HemaSphere"},{"issue":"33","key":"10.1053\/j.seminhematol.2025.04.004_bib0013","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1200\/JCO.22.02830","article-title":"Zanubrutinib versus Ibrutinib in symptomatic Waldenstrom Macroglobulinemia: final analysis from the randomized phase III ASPEN study","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.04.004_bib0014","doi-asserted-by":"crossref","first-page":"E184","DOI":"10.1002\/ajh.26133","article-title":"Real-world treatment patterns and outcomes in a national study of veterans with Waldenstr\u00f6m Macroglobulinemia, 2006\u20132019","volume":"96","author":"Chien","year":"2021","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.04.004_bib0015","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/bjh.18643","article-title":"Dose reductions in patients with Waldenstrom Macroglobulinaemia treated with ibrutinib","volume":"201","author":"Sarosiek","year":"2023","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.04.004_bib0016","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2352-3026(22)00320-9","article-title":"Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study","volume":"10","author":"Shadman","year":"2023","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.04.004_bib0017","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.3324\/haematol.2020.272500","article-title":"Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"106","author":"Rogers","year":"2021","journal-title":"Haematologica"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.004_bib0018","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.seminhematol.2023.03.009","article-title":"Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on diagnostic and response criteria","volume":"60","author":"Treon","year":"2023","journal-title":"Semin Hematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.04.004_bib0019","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.3324\/haematol.2017.186908","article-title":"Ibrutinib withdrawal symptoms in patients with Waldenstrom Macroglobulinemia","volume":"103","author":"Castillo","year":"2018","journal-title":"Haematologica"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.04.004_bib0020","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1002\/cncr.20658","article-title":"Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom Macroglobulinemia: an Eastern Cooperative Oncology Group Study","volume":"101","author":"Ghobrial","year":"2004","journal-title":"Cancer"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.04.004_bib0021","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/annonc\/mdh403","article-title":"Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's Macroglobulinemia","volume":"15","author":"Treon","year":"2004","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1053\/j.seminhematol.2025.04.004_bib0022","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1053\/j.seminhematol.2025.04.004_bib0023","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1182\/blood-2017-10-811752","article-title":"BTK(Cys481Ser) drives ibrutinib resistance via ERK1\/2 and protects BTK(wild-type) MYD88-mutated cells by a paracrine mechanism","volume":"131","author":"Chen","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.04.004_bib0024","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.04.004_bib0025","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/bjh.16463","article-title":"Genomic evolution of ibrutinib-resistant clones in Waldenstrom Macroglobulinaemia","volume":"189","author":"Jimenez","year":"2020","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.04.004_bib0026","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.16088","article-title":"CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstrom Macroglobulinaemia treated with ibrutinib","volume":"187","author":"Castillo","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.004_bib0027","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjh.15560","article-title":"TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenstrom Macroglobulinaemia","volume":"184","author":"Gustine","year":"2019","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1053\/j.seminhematol.2025.04.004_bib0028","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","article-title":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom Macroglobulinemia","volume":"123","author":"Treon","year":"2014","journal-title":"Blood"},{"issue":"20","key":"10.1053\/j.seminhematol.2025.04.004_bib0029","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1158\/1078-0432.CCR-17-0007","article-title":"TP53 Mutation and its prognostic significance in Waldenstrom's Macroglobulinemia","volume":"23","author":"Poulain","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.04.004_bib0030","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1182\/bloodadvances.2023010906","article-title":"Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenstrom Macroglobulinemia","volume":"8","author":"Tam","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.04.004_bib0031","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.16168","article-title":"Ibrutinib monotherapy outside of clinical trial setting in Waldenstrom Macroglobulinaemia: practice patterns, toxicities and outcomes","volume":"188","author":"Abeykoon","year":"2020","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.04.004_bib0032","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3324\/haematol.2021.279112","article-title":"Natural history of Waldenstrom Macroglobulinemia following acquired resistance to ibrutinib monotherapy","volume":"107","author":"Gustine","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.04.004_bib0033","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.21.01194","article-title":"Venetoclax in previously treated Waldenstrom Macroglobulinemia","volume":"40","author":"Castillo","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.04.004_bib0034","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1182\/blood-2022-159123","article-title":"Efficacy of Pirtobrutinib, a highly selective, non-covalent (Reversible) BTK inhibitor in relapsed \/refractory Waldenstr\u00f6m macroglobulinemia: results from the phase 1\/2 BRUIN study","volume":"140","author":"Palomba","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.04.004_bib0035","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood.2023022420","article-title":"Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naive Waldenstrom Macroglobulinemia","volume":"143","author":"Castillo","year":"2024","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2025.04.004_bib0036","doi-asserted-by":"crossref","first-page":"TPS7090","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7090","article-title":"BGB-11417-203: an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenstr\u00f6m Macroglobulinemia","volume":"42","author":"Lee","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.04.004_bib0037","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood-2024-199212","article-title":"Preliminary efficacy and safety of the Bruton Tyrosine Kinase degrader BGB-16673 in patients with relapsed or refractory Waldenstr\u00f6m macroglobulinemia: results from the phase 1 CaDAnCe-101 study","volume":"144","author":"Seymour","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.04.004_bib0038","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1182\/blood-2024-198297","article-title":"A Phase II study of Pirtobrutinib and Venetoclax in previously treated patients with Waldenstr\u00f6m macroglobulinemia: an interim analysis","volume":"144","author":"Castillo","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.04.004_bib0039","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1182\/blood-2024-200277","article-title":"Iopofosine I 131 in previously treated patients with Waldenstr\u00f6m Macroglobulinemia (WM): efficacy and safety results from the International, Multicenter, open-label phase 2 study (CLOVER-WaM\u2122)","volume":"144","author":"Ailawadhi","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.04.004_bib0040","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.1182\/blood-2024-211573","article-title":"A Phase II trial of Loncastuximab Tesirine in patients with previously treated Waldenstr\u00f6m Macroglobulinemia","volume":"144","author":"Castillo","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.04.004_bib0041","doi-asserted-by":"crossref","first-page":"6294","DOI":"10.1182\/blood-2024-206415","article-title":"A phase 2 trial investigating Epcoritamab in patients with previously treated Waldenstrom Macroglobulinemia (WM)\/lymphoplasmacytic lymphoma (WM-NET3)","volume":"144","author":"von Keudell","year":"2024","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T13:22:42Z","timestamp":1750857762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196325000149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0037196325000149"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.04.004","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}